News for BioXcel Therapeutics, Inc. (BTAI)

Published at

Jul 21, 2025 2:22 PM

by gurufocus.com

positive

positive

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI® | BTAI Stock News

BioXcel Therapeutics (BTAI) has submitted a pre-sNDA to the FDA for IGALMI, targeting a label expansion for at-home use in acute agitation treatment. Th

BTAI

Read more →
Published at

Jul 21, 2025 2:18 PM

by gurufocus.com

positive

positive

BioXcel Therapeutics (BTAI) Seeks FDA Approval for Expanded IGALMI Use | BTAI Stock News

BioXcel Therapeutics (BTAI) is moving forward with plans to expand the use of its drug, IGALMI. The company has submitted a pre-supplemental New Drug Applicatio

BTAI

Read more →
Published at

Jul 21, 2025 2:00 PM

by gurufocus.com

positive

positive

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizop

BTAI

Read more →
Published at

Jul 15, 2025 5:30 PM

by gurufocus.com

positive

positive

BTAI: BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets | BTAI Stock News

On July 15, 2025, BioXcel Therapeutics (BTAI) received an update from analyst Elemer Piros of Lucid Capital Markets, who reaffirmed their "Buy" rating for the s

BTAI

Read more →
Published at

Jul 15, 2025 5:17 PM

by gurufocus.com

negative

negative

BioXcel Therapeutics (BTAI) Secures Patent for Dexmedetomidine Use | BTAI Stock News

BioXcel Therapeutics (BTAI) has revealed that the U.S. Patent and Trademark Office has permitted U.S. Patent Application No. 18/600,419. This patent involves th

BTAI

Read more →
Published at

Jul 12, 2025 1:27 AM

by insidermonkey.com

positive

positive

BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright analysts have reiterated their Buy rating on BioXcel Therapeutics, Inc.

BTAI

Read more →
Published at

Jun 23, 2025 8:50 PM

by gurufocus.com

neutral

neutral

H.C. Wainwright Boosts Price Target for BioXcel Therapeutics (BTAI) | BTAI Stock News

H.C. Wainwright has increased its price target for BioXcel Therapeutics (BTAI), moving it up to $8 from the previous $3, while maintaining a Buy rating on the s

BTAI

Read more →
Published at

Jun 23, 2025 3:00 PM

by gurufocus.com

positive

positive

BioXcel Therapeutics (BTAI) Sees Significant Price Target Upgrade | BTAI Stock News

BioXcel Therapeutics (BTAI) has received a substantial price target upgrade from HC Wainwright & Co., as reported on June 23, 2025. The firm's analyst, Raghuram

BTAI

Read more →
Published at

May 30, 2025 5:00 PM

by gurufocus.com

positive

positive

Real-World Deployments Signal AI Healthcare Is Ready for Scale

PR NewswireVANCOUVER, BC, May 30, 2025 Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc.VANCOUVER, BC, May 30, 2025 /PRNewswire/ --

WLYYF WELL.TO TEM BTAI

Read more →
Published at

May 27, 2025 3:45 PM

by gurufocus.com

neutral

neutral

BTAI's Phase 3 Trial for BXCL501 Advances Unhindered by Safety Concerns | BTAI Stock News

BioXcel Therapeutics (BTAI) has announced that their ongoing SERENITY At-Home Phase 3 trial for BXCL501, aimed at treating acute agitation in bipolar disorder o

BTAI

Read more →
Published at

May 27, 2025 3:17 PM

by gurufocus.com

positive

positive

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated wit

The Data Safety Monitoring Board (DSMB) has recommended continuing BioXcel Therapeutics' Phase 3 SERENITY At-Home trial without modifications. The trial

BTAI

Read more →
Published at

May 27, 2025 3:01 PM

by gurufocus.com

neutral

neutral

BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq Listing

BioXcel Therapeutics granted extension by Nasdaq to meet listing requirements. Analyst projections show significant potential upside for BTAI stock. Curren

BTAI

Read more →
Published at

May 27, 2025 2:30 PM

by gurufocus.com

positive

positive

BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | BTAI Stock News

BioXcel Therapeutics (BTAI) has successfully been granted an extension to remain listed on the Nasdaq Stock Market. Following a hearing with the Nasdaq Hearings

BTAI

Read more →
Published at

May 27, 2025 2:00 PM

by gurufocus.com

positive

positive

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ( BTAI), a biopharmaceutical company utilizing artificial intelligence to develo

BTAI

Read more →
Published at

May 12, 2025 2:20 PM

by gurufocus.com

neutral

neutral

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | BTAI Stock News

BioXcel Therapeutics (BTAI) completed enrollment for the SERENITY At-Home Phase 3 trial with 200 patients. Q1 2025 net loss improved to $7.3 million fro

BTAI

Read more →
Published at

May 12, 2025 2:15 PM

by gurufocus.com

positive

positive

BioXcel Therapeutics (BTAI) Reports Major Milestone in BXCL501 Trial | BTAI Stock News

BioXcel Therapeutics (BTAI) announced a revenue of $168,000, a decrease from last year's $582,000. The company reached a significant milestone with its initial

BTAI

Read more →
Published at

May 12, 2025 2:15 PM

by zacks.com

negative

negative

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 44.85% and 44%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

BTAI

Read more →
Published at

May 12, 2025 2:00 PM

by gurufocus.com

neutral

neutral

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia Topl

BTAI

Read more →
Published at

Apr 16, 2025 3:57 PM

by manilatimes.net

mixed

mixed

WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market

Equity Insider News Commentary

MSFT AMST PTX.DE PLTR BTAI 0A7R.L

Read more →
Published at

Mar 27, 2025 1:15 PM

by zacks.com

positive

positive

BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 18.12% and 144%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

BTAI

Read more →